According to The Insight Partners market research study of ‘Transdermal Drug Delivery System Market to 2027 – Global Analysis and Forecasts by Type, Application, and End User,’ the global transdermal drug delivery system market is expected to reach US$ 8,415.04 million in 2027 from US$ 6,063.85 million in 2019.
According to The Insight Partners market research study of ‘Transdermal Drug Delivery System Market to 2027 – Global Analysis and Forecasts by Type, Application, and End User,’ the global transdermal drug delivery system market is expected to reach US$ 8,415.04 million in 2027 from US$ 6,063.85 million in 2019. The market is estimated to grow at a CAGR of 4.3% from 2020 to 2027. The report highlights trends prevailing in the global transdermal drug delivery system market and the factors driving market along with those that act as hindrances.
Transdermal Drug Delivery System (TDDS) is described as a self-contained or discrete dosage form known as patches or semisolid forms that are applied to the intact skin. There are different types of semisolid forms, such as, creams, ointments, gels, and sprays. Dosage forms are designed to deliver a therapeutically effective amount of drug across a patient’s skin. The transdermal drug delivery system market is expected to witness a huge growth due to increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.
Request for sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00002894/
Transdermal Drug Delivery System Market Competitive Landscape and Key Development
Novartis Ag, Johnson & Johnson Services, Inc., Glaxosmithkline Plc., Bayer Ag, Mylan N.V., Boehringer Ingelheim International Gmbh, Hisamitsu Pharmaceutical Co.,Inc., Luye Pharma Group, Purdue Pharma L.P., and Lavipharm are among the leading companies operating in the transdermal drug delivery system market.
The transdermal drug delivery system market is expected to grow owing to factors such as increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, high cost involved in the development of drug delivery systems along with drug failure and recalls of transdermal drug delivery systems are likely to restraint the growth of the market during the forecast years.
Growing Demand for Non-Invasive Drug Delivery Devices
With the improvements in medical science and definite oral drug delivery technologies, the non-invasive mode of drug delivery system is now prepared to compete with traditional methods of injectable and painful routes of drug delivery. The non-invasive drug delivery systems include drug delivery via oral, topical, transdermal-active (device-aided enhanced penetration), transdermal-passive, trans-ocular membrane, trans-mucosal membrane, and via alveolar membrane from inhaled medication. Transdermal delivery has a range of advantages compared to the oral route. In particular, it is used when there is a significant first-pass effect of the liver that can impulsively metabolize drugs. Transdermal delivery also has advantages over hypodermic injections, which are painful, create dangerous medical waste, and pose the risk of disease transmission by needle re-use, especially in developing countries. Additionally, transdermal systems are non-invasive and can be self-administered. Patient compliance has been found to be much higher when administrated by non-invasive routes due to decreased pain involved in drug delivery. Therefore, these techniques are considered a preferred mode of drug delivery, thereby driving the market growth in the review period.
Type-Based Insights
Based on type, the transdermal drug delivery system market is segmented into transdermal patches and transdermal semisolids. The transdermal patch segment is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and micro needle patches. The transdermal semisolids segment is further sub segmented into gels, ointments, and sprays. The transdermal patches segment held the larger share of the market in 2019, owing to the advantages such as better patient compliance, faster onset of action, and improved permeability and efficacy. Also, the transdermal patches segment is expected to register a higher CAGR in the market during the forecast period. Additionally, growing emphasis on implementation of inorganic strategies to elevate manufacturing capacity is also projected to drive the transdermal patches segment growth. For instance, in August 2019, Canoa Inc. announced its plan to acquire privately-held ProSolus Inc. to accelerate transdermal drug delivery product development. This strategic acquisition will consolidate company’s transdermal drug delivery products manufacturing capacity.
Based on application, the transdermal drug delivery system market is segmented into pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications. The hormonal applications segment is further sub segmented into transdermal estrogen therapy and testosterone replacement. In 2019, the pain management segment accounted for the largest share of the global transdermal drug delivery system market owing to increasing number of transdermal drug delivery systems for the pain management. Also, pain management segment is estimated to register the highest CAGR in the market during the forecast period.
Buy Complete Report of Transdermal Drug Delivery System Market Study at: https://www.theinsightpartners.com/buy/TIPRE00002894/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
E-mail: sam@theinsightpartners.com